| First Author | Vogt A | Year | 2005 |
| Journal | J Invest Dermatol | Volume | 124 |
| Issue | 1 | Pages | 263-7 |
| PubMed ID | 15654983 | Mgi Jnum | J:95379 |
| Mgi Id | MGI:3525923 | Doi | 10.1111/j.0022-202X.2004.23573.x |
| Citation | Vogt A, et al. (2005) Anti-rejection drug treatment increases Basal cell carcinoma burden in ptch1+/- mice. J Invest Dermatol 124(1):263-7 |
| abstractText | The development of extensive and severe non-melanoma skin cancer is an extremely common complication of organ transplantation and is assumed to be caused by long-term treatment with anti-rejection drugs (ARD). Despite this florid clinical problem, ARD treatments have been reported to affect experimental murine skin carcinogenesis only weakly. We report here that treatment of cesium-137-irradiated Ptch1+/- mice with immunosuppressive doses of cyclosporine A plus prednisolone for 4-1/2 mo increased basal cell carcinoma burden by 2.5-fold. Thus, these mice provide a good model for study of the effects of long-term administration of ARD on at least one type of non-melanoma skin cancer. |
